The papillomavirus major capsid protein, L1, is a ~55 kD protein with the ability to spontaneously self-assemble into virus-like particles (VLPs). These VLPs present an exterior surface essentially indistinguishable from the native 60 nm non-enveloped papillomavirus virion. Meanwhile, purified recombinant L1 proteins can achieve complex assembly reactions in the absence of any chaperones, and related assembled VLPs are potent immunogens as well.
Creative Diagnostics has developed a number of neutralizing antibodies against HPV L1, and the activities of these antibodies have been extensively validated in pseudovirus infection assays.
Performance
•
These antibodies are obtained by immunization and screening of L1-VLP expressed in E. coli
•
These antibodies have no or relatively weak response to L1 expressed in other different systems or processes
•
These antibodies have been proven to be useful for ELISA but not for WB
•
Neutralization activity has been confirmed using Pseudotyped GFP HPV
•
Each set contains six clones and different clones can be elected for sandwich immunoassay
•
Each clone can be sold separately and used in vaccine development
Creative Diagnostics has established the global-leading virus-like particles (VLPs) manufacturing platform using the E. coli cell system. With years of exploration, our scientists have successfully obtained various highly purified HPV VLPs. Meanwhile, our products have widely contributed to HPV vaccine-related research.
Immunogenicity assessments in vaccine trials have focused on measuring antibody responses to the vaccine. A series of functional assays have been generated to measure antibody-mediated neutralization for papillomaviruses, while some functional assays involve highly complex animal challenges and cannot be applied for routine testing.
